This is an aggregated industry headline. Read the full story at FierceBiotech →
'It looks like this hypothesis will pan out': Cullinan unveils data building case for autoimmune TCEs
When it comes to turning T-cell therapies toward autoimmune diseases, CAR-Ts have been leading the way. But another red-hot modality is also beginning to show potential in the clinic.
By FierceBiotech
· Jun 6, 2026
· via FierceBiotech
Image: FierceBiotech
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Widespread misconceptions about Type 1 diabetes could be contributing to a reluctance to get screened for the …
The WeekFierceBiotech ↗
Bristol Myers Squibb has entered into an expanded collaboration with Nvidia to create the biggest supercompute…
The WeekBriefing
Medicare’s proposal to trim hospital reimbursement for specific drugs and imaging services could extend site-n…